Polypharmacy prior to in-hospital cardiac arrest among patients with cardiopulmonary diseases: A pilot study.

In-hospital cardiac arrest Initial Rhythms of Cardiac Arrest Polypharmacy Survival

Journal

Resuscitation plus
ISSN: 2666-5204
Titre abrégé: Resusc Plus
Pays: Netherlands
ID NLM: 101774410

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 10 5 2021
pubmed: 11 5 2021
medline: 11 5 2021
Statut: ppublish

Résumé

Patterns of medication administration prior to in-hospital cardiac arrest (I-HCA) and the potential impact of these on patient outcomes is not well-established. Accordingly, types of medications administered in the 72 h prior to I-HCA were examined in relation to initial rhythms of I-HCA and survival. A retrospective, pilot study was conducted among 96 patients who experienced I-HCA. Clinical characteristics and treatments including medications were extracted from electronic health records. Relative risk (RR) of medications or class of medications associated with the initial rhythms of I-HCA and return of spontaneous circulation (ROSC) were calculated. Two distinct sub-groups were identified that did not survive to hospital discharge (n = 31): 1) those who received either vasopressin/desmopressin (n = 16) and 2) those who received combinations of psychotherapeutic agents with anxiolytics, sedatives, and hypnotics (n = 15) prior to I-HCA. The risk of pulseless electrical activity and asystolic arrest was high in patients who received sympathomimetic agents alone or in combination with β-Adrenergic blocking agents, (RR = 1.40, 1.41, respectively). Vasopressin and a combination of vasopressin and fentanyl were associated with risk of unsuccessful ROSC (RR = 2.50, 2.38, respectively). The types of medications administered during inpatient care may serve as a surrogate marker for identifying patients at risk of specific initial rhythms of I-HCA and survival.

Sections du résumé

BACKGROUND BACKGROUND
Patterns of medication administration prior to in-hospital cardiac arrest (I-HCA) and the potential impact of these on patient outcomes is not well-established. Accordingly, types of medications administered in the 72 h prior to I-HCA were examined in relation to initial rhythms of I-HCA and survival.
METHODS METHODS
A retrospective, pilot study was conducted among 96 patients who experienced I-HCA. Clinical characteristics and treatments including medications were extracted from electronic health records. Relative risk (RR) of medications or class of medications associated with the initial rhythms of I-HCA and return of spontaneous circulation (ROSC) were calculated.
RESULTS RESULTS
Two distinct sub-groups were identified that did not survive to hospital discharge (n = 31): 1) those who received either vasopressin/desmopressin (n = 16) and 2) those who received combinations of psychotherapeutic agents with anxiolytics, sedatives, and hypnotics (n = 15) prior to I-HCA. The risk of pulseless electrical activity and asystolic arrest was high in patients who received sympathomimetic agents alone or in combination with β-Adrenergic blocking agents, (RR = 1.40, 1.41, respectively). Vasopressin and a combination of vasopressin and fentanyl were associated with risk of unsuccessful ROSC (RR = 2.50, 2.38, respectively).
CONCLUSIONS CONCLUSIONS
The types of medications administered during inpatient care may serve as a surrogate marker for identifying patients at risk of specific initial rhythms of I-HCA and survival.

Identifiants

pubmed: 33969325
doi: 10.1016/j.resplu.2020.100026
pmc: PMC8104360
mid: NIHMS1691259
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCATS NIH HHS
ID : TL1 TR000096
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR002000
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD012397
Pays : United States

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no conflicts of interests.

Références

BMJ. 2017 Jul 6;358:j2941
pubmed: 28684397
Int J Clin Pharm. 2018 Oct;40(5):1342-1348
pubmed: 29987511
PLoS One. 2018 Mar 22;13(3):e0194553
pubmed: 29566020
J Pharm Pract. 2019 Jun;32(3):271-291
pubmed: 30955461
N Engl J Med. 2019 Dec 12;381(24):2327-2337
pubmed: 31577396
Int J Cardiol. 2016 Dec 1;224:366-375
pubmed: 27673693
Curr HIV/AIDS Rep. 2018 Jun;15(3):233-244
pubmed: 29752699
Int J Clin Pract. 2017 Oct;71(10):
pubmed: 28869702
Resuscitation. 2003 Sep;58(3):297-308
pubmed: 12969608
Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):889-95
pubmed: 25351479
Cochrane Database Syst Rev. 2018 Nov 23;11:CD009783
pubmed: 30484283
Eur J Clin Pharmacol. 1996;49(4):261-5
pubmed: 8857070
J Hosp Med. 2017 Jun;12(6):428-434
pubmed: 28574532
Anaesthesia. 2019 Mar;74(3):380-392
pubmed: 30367689
Ther Adv Drug Saf. 2017 Mar;8(3):101-111
pubmed: 28382198
Psychother Psychosom. 2018;87(6):372-374
pubmed: 30304738
N Engl J Med. 2015 Apr 2;372(14):1333-41
pubmed: 25830423
JAMA. 2017 Apr 4;317(13):1321-1328
pubmed: 28322414
Cochrane Database Syst Rev. 2019 Jan 17;1:CD003179
pubmed: 30653257
Br J Clin Pharmacol. 2007 Feb;63(2):216-23
pubmed: 16869820
Eur J Intern Med. 2016 Jan;27:14-23
pubmed: 26553001
Resuscitation. 2012 Jan;83(1):63-9
pubmed: 21963583
Resuscitation. 2019 Mar;136:93-99
pubmed: 30710595
PLoS One. 2016 Feb 25;11(2):e0150214
pubmed: 26913753
Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005429
pubmed: 30871337
Am Heart J. 2018 Aug;202:139-143
pubmed: 29859617
Anaesth Intensive Care. 2015 Mar;43(2):175-86
pubmed: 25735682
J Am Coll Cardiol. 2018 Jan 30;71(4):402-411
pubmed: 29389356
J Am Heart Assoc. 2014 Dec;3(6):e001044
pubmed: 25520328
Cochrane Database Syst Rev. 2018 Jun 18;6:CD005594
pubmed: 29920656
Endocr Rev. 2010 Feb;31(1):98-132
pubmed: 19903933
Heart. 2009 Dec;95(23):1901-6
pubmed: 19666461
Postgrad Med. 2015 Apr;127(3):330-7
pubmed: 25539567
Bioinformatics. 2018 Jul 1;34(13):i457-i466
pubmed: 29949996
Atherosclerosis. 2014 Aug;235(2):496-502
pubmed: 24953489
J Geriatr Cardiol. 2018 Jun;15(6):451-459
pubmed: 30108618
Resuscitation. 2017 Dec;121:84-89
pubmed: 29037885
Psychiatr Clin North Am. 2016 Jun;39(2):275-311
pubmed: 27216904
J Crit Care. 2015 Dec;30(6):1376-81
pubmed: 26428074
Ann Pharmacother. 2017 Jan;51(1):13-20
pubmed: 27630192
Int J Psychiatry Clin Pract. 2019 Jun;23(2):134-148
pubmed: 30707042

Auteurs

Mina Attin (M)

School of Nursing, University of Rochester, NY, USA.

Simeon Abiola (S)

Clinical and Translational Science Institute, School of Medicine and Dentistry, University of Rochester, NY, USA.

Rijul Magu (R)

School of Nursing, University of Rochester, NY, USA.

Spencer Rosero (S)

Division of Cardiology, Cardiac Electrophysiology, Department of Medicine, University of Rochester, NY, USA.

Michael Apostolakos (M)

Division of Pulmonary Diseases, Critical Care, Department of Medicine, University of Rochester, NY, USA.

Christine M Groth (CM)

Division of Pharmacy, Department of Medicine, University of Rochester, NY, USA.

Robert Block (R)

Division of Cardiology, Department of Medicine, University of Rochester, NY, USA.

C D Joey Lin (CDJ)

Department of Mathematics and Statistics, San Diego State University, San Diego, USA.

Orna Intrator (O)

Department of Public Health Sciences, School of Medicine and Dentistry, University of Rochester, Rochester, New York, Geriatrics & Extended Care Data & Analysis Center (GEC DAC), Canandaigua Veterans Affairs Medical Center, Canandaigua, NY, USA.

Deborah Hurley (D)

Department of Learning and Development in the University of Rochester Medical Center, Rochester, NY, USA.

Kimberly Arcoleo (K)

University of Rode Island, College of Nursing, NY, USA.

Classifications MeSH